Zimbabwe has rejected a major US health deal valued at $367m (272 million pounds) spanning five years due to Washington's demand for sensitive data.
This move became public following a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson later stated that the United States was requesting genetic material for scientific study and profit but was not willing to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued talks to reach a deal suitable to all parties so the country's vital HIV programme can proceed.
Wider Background
Zimbabwe's decision follows a similar case in Kenya, where a court blocked a similar health funding agreement after concerns were raised about the safety of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral deals to boost transparency and responsibility.
According to reports, Sixteen African countries have so far agreed to these new health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, without any corresponding guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Put simply, our country would supply the basic resources for medical research without any certainty that the end products would be available to our population should a future pandemic arise."
Sovereignty and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending systems already set up through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage future global health emergencies.
"This mechanism is designed to guarantee that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome ongoing dialogue with our US partners on how subsequent collaboration might be designed in a way that honours the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but recommended that talks must proceed considering much of the nation's Aids initiatives were funded by external financing.
"Where specific concerns exist, such as those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," the group commented.
The situation underscores the continuing tensions between accepting vital international aid and safeguarding local interests in an ever more data-driven world.